53
Participants
Start Date
February 28, 2013
Primary Completion Date
December 31, 2014
Study Completion Date
December 31, 2014
NNC0114-0006
A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
placebo
A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
Novo Nordisk Investigational Site, Sofia
Novo Nordisk Investigational Site, Sofia
Novo Nordisk Investigational Site, Varna
Novo Nordisk Investigational Site, Prague
Novo Nordisk Investigational Site, Madrid
Novo Nordisk Investigational Site, Miami
Novo Nordisk Investigational Site, Clearwater
Novo Nordisk Investigational Site, Jackson
Novo Nordisk Investigational Site, Santander
Novo Nordisk Investigational Site, Seville
Novo Nordisk Investigational Site, Seville
Novo Nordisk Investigational Site, Valencia
Novo Nordisk Investigational Site, Jefferson City
Novo Nordisk Investigational Site, Little Rock
Novo Nordisk Investigational Site, Little Rock
Novo Nordisk Investigational Site, Houston
Novo Nordisk Investigational Site, Olomouc
Novo Nordisk Investigational Site, Tucson
Novo Nordisk Investigational Site, Laguna Hills
Novo Nordisk Investigational Site, Hradec Králové
Novo Nordisk Investigational Site, Olomouc
Novo Nordisk Investigational Site, Częstochowa
Novo Nordisk Investigational Site, Szczecin
Novo Nordisk Investigational Site, Banská Bystrica
Novo Nordisk Investigational Site, Bratislava
Novo Nordisk Investigational Site, Ružomberok
Novo Nordisk Investigational Site, Barcelona
Novo Nordisk Investigational Site, Barcelona
Lead Sponsor
Novo Nordisk A/S
INDUSTRY